Cargando…
Hypertrophic, Dilated, and Arrhythmogenic Cardiomyopathy: Where Are We?
Cardiomyopathies are a heterogeneous group of structural, mechanical, and electrical heart muscle disorders which often correlate with life-threatening arrhythmias and progressive heart failure accounting for significant cardiovascular morbidity and mortality. Currently, cardiomyopathies still repre...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953324/ https://www.ncbi.nlm.nih.gov/pubmed/36831060 http://dx.doi.org/10.3390/biomedicines11020524 |
_version_ | 1784893850219708416 |
---|---|
author | El Hadi, Hamza Freund, Anne Desch, Steffen Thiele, Holger Majunke, Nicolas |
author_facet | El Hadi, Hamza Freund, Anne Desch, Steffen Thiele, Holger Majunke, Nicolas |
author_sort | El Hadi, Hamza |
collection | PubMed |
description | Cardiomyopathies are a heterogeneous group of structural, mechanical, and electrical heart muscle disorders which often correlate with life-threatening arrhythmias and progressive heart failure accounting for significant cardiovascular morbidity and mortality. Currently, cardiomyopathies still represent a leading reason for heart transplantation worldwide. The last years have brought remarkable advances in the field of cardiomyopathies especially in terms of understanding the molecular basis as well as the diagnostic evaluation and management. Although most cardiomyopathy treatments had long focused on symptom management, much of the current research efforts aim to identify and act on the disease-driving mechanisms. Regarding risk assessment and primary prevention of sudden cardiac death, additional data are still pending in order to pave the way for a more refined and early patient selection for defibrillator implantation. This review summarizes the current knowledge of hypertrophic, dilated and arrhythmogenic cardiomyopathy with a particular emphasis on their pathophysiology, clinical features, and diagnostic approach. Furthermore, the relevant ongoing studies investigating novel management approaches and main gaps in knowledge are highlighted. |
format | Online Article Text |
id | pubmed-9953324 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99533242023-02-25 Hypertrophic, Dilated, and Arrhythmogenic Cardiomyopathy: Where Are We? El Hadi, Hamza Freund, Anne Desch, Steffen Thiele, Holger Majunke, Nicolas Biomedicines Review Cardiomyopathies are a heterogeneous group of structural, mechanical, and electrical heart muscle disorders which often correlate with life-threatening arrhythmias and progressive heart failure accounting for significant cardiovascular morbidity and mortality. Currently, cardiomyopathies still represent a leading reason for heart transplantation worldwide. The last years have brought remarkable advances in the field of cardiomyopathies especially in terms of understanding the molecular basis as well as the diagnostic evaluation and management. Although most cardiomyopathy treatments had long focused on symptom management, much of the current research efforts aim to identify and act on the disease-driving mechanisms. Regarding risk assessment and primary prevention of sudden cardiac death, additional data are still pending in order to pave the way for a more refined and early patient selection for defibrillator implantation. This review summarizes the current knowledge of hypertrophic, dilated and arrhythmogenic cardiomyopathy with a particular emphasis on their pathophysiology, clinical features, and diagnostic approach. Furthermore, the relevant ongoing studies investigating novel management approaches and main gaps in knowledge are highlighted. MDPI 2023-02-11 /pmc/articles/PMC9953324/ /pubmed/36831060 http://dx.doi.org/10.3390/biomedicines11020524 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review El Hadi, Hamza Freund, Anne Desch, Steffen Thiele, Holger Majunke, Nicolas Hypertrophic, Dilated, and Arrhythmogenic Cardiomyopathy: Where Are We? |
title | Hypertrophic, Dilated, and Arrhythmogenic Cardiomyopathy: Where Are We? |
title_full | Hypertrophic, Dilated, and Arrhythmogenic Cardiomyopathy: Where Are We? |
title_fullStr | Hypertrophic, Dilated, and Arrhythmogenic Cardiomyopathy: Where Are We? |
title_full_unstemmed | Hypertrophic, Dilated, and Arrhythmogenic Cardiomyopathy: Where Are We? |
title_short | Hypertrophic, Dilated, and Arrhythmogenic Cardiomyopathy: Where Are We? |
title_sort | hypertrophic, dilated, and arrhythmogenic cardiomyopathy: where are we? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953324/ https://www.ncbi.nlm.nih.gov/pubmed/36831060 http://dx.doi.org/10.3390/biomedicines11020524 |
work_keys_str_mv | AT elhadihamza hypertrophicdilatedandarrhythmogeniccardiomyopathywherearewe AT freundanne hypertrophicdilatedandarrhythmogeniccardiomyopathywherearewe AT deschsteffen hypertrophicdilatedandarrhythmogeniccardiomyopathywherearewe AT thieleholger hypertrophicdilatedandarrhythmogeniccardiomyopathywherearewe AT majunkenicolas hypertrophicdilatedandarrhythmogeniccardiomyopathywherearewe |